N/A N=146 Aspiration of Residual Gastric Contents
Infant, Premature · Nutrition, Enteral
Primary: Enteral Intake on Day of Life 7 — 27.5; 22.6 mL/kg per day — p=0.27
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=65 Nasal Decolonization for Orthopedic Trauma Patients
Surgical Site Infection
Primary: Number of Participants With Staphylococcus Aureus Nasal Colonization — 12 Participants
Phase 3 N=18 Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years
Cystic Fibrosis
Primary: Part A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites — 0.00; 3.44; 3.69; 0.00 micrograms per milliliter (mcg/ml)
N/A N=73 Effect of Clear Aligner Attachment Design on Extrusion of Maxillary Lateral Incisors
Maxillary Lateral Incisor Malocclusion
Primary: Percent of Vertical Tooth Movement — 79; 78; 78; 62 percentage of predicted
Phase 2 N=6 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia
Primary: Time to Engraftment — 2; 1; 1; 1 Participants
N/A N=101 Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Benign Prostatic Hyperplasia (BPH)
Primary: Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment — 45.5 percentage
N/A N=40 Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
Cancer · Survivorship · Hematopoietic and Lymphoid Cell Neoplasm
Primary: Number of Patients Enrolled Out of Those Electronically Referred — 40 number of participants — p=0.54
N/A N=102 The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
Type 1 Diabetes
Primary: Time in Range — 56.7; 54.9; 69.3; 55.9 Percent of time — p=<0.001
N/A N=17 Sound Quality Comparisons With Different Hearing Aid Couplings and Venting Systems
Hearing Loss, Sensorineural
Primary: Sound Quality of Streamed Music Rating Scale — 84; 70; 70; 90 score on a scale — p=0.012
Phase 3 N=274 Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
Hospital-Acquired Bacterial Pneumonia · Ventilator-Associated Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality Through Day 28 in the Modified Intent to Treat (MITT) Population — 11.2; 5.9 Percentage of Participants — p=0.024
Phase 2 N=275 A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
Resistant Hypertension
Primary: Change From Baseline in Mean Seated Systolic BP (SBP) — -12.4; -17.3; -19.2; -9.8 mmHg
Phase 2 N=78 A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
Cystic Fibrosis
Primary: Absolute Change From Baseline Through Day 29 in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — 0.3; -2.2; 2.0; 4.5 percent predicted FEV1 (%)
N/A N=8 Noninvasive Ventilation Masks Carbon Dioxide Clearance in Normal Volunteers
CO2 Clearance · Mask Comfort · Rebreathing Exhaled Gas
Primary: Carbon Dioxide Clearance From the Masks — 1.83; 1; 0.49; 0 percentage of CO2 inspired
N/A N=47 Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia
Preeclampsia With Severe Features
Primary: Duration of Magnesium Sulfate Use in the Postpartum Period Defined as the Duration in Hours Between Delivery and Discontinuation of Magnesium Sulfate. — 21.6; 24 hours
N/A N=211 Improving Chronic Illness Management With the Apsaalooke Nation: The Baa Nnilah Project
Chronic Disease
Primary: SF-12 - Physical Health — 43.85; 43.64; 45.65; 45.18 score on a scale — p=0.50